ACE2 and COVID-19: Upregulation of ACE2 expression and activity in response RAS blockade was reported to be consistent for ARB therapy, while it was variable with ACE-I administration.5,8 We have examined ACE-I and ARB therapies separately; neither showed an association with COVID-19 severity, according to the WHO criteria.